Skip to main content

Lorbrena FDA Approval History

Last updated by Judith Stewart, BPharm on March 10, 2021.

FDA Approved: Yes (First approved November 2, 2018)
Brand name: Lorbrena
Generic name: lorlatinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Non Small Cell Lung Cancer

Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.

Development timeline for Lorbrena

DateArticle
Mar  3, 2021Approval U.S. FDA Expands Approval of Pfizer’s Lorbrena as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
Nov  2, 2018Approval FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
Feb 12, 2018U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-generation ALK Inhibitor Lorlatinib
Oct 16, 2017Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

See also

Lorbrena (lorlatinib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer